Finasteride FDA Approval History: Dates, Labels, and Safety Updates

The Two FDA Approvals: Proscar and Propecia

Finasteride reached the market through two distinct New Drug Applications. Proscar (5 mg) was approved June 19, 1992, for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Propecia (1 mg) followed on December 22, 1997, specifically for the treatment of male-pattern hair loss (androgenetic alopecia) in men only.

Proscar: The 1992 BPH Approval

The original NDA for Proscar (NDA 020145) was anchored to key phase III data showing that finasteride 5 mg reduced prostate volume by approximately 20% over 12 months and improved peak urinary flow rates compared with placebo. The FDA Center for Drug Evaluation and Research (CDER) reviewed the submission under standard review timelines, and the agency's approval letter established finasteride as the first 5-alpha reductase inhibitor to reach U.S. Patients [1].

The labeled indication at approval was narrow: treatment of symptomatic BPH in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery. The 5 mg dose was selected because it produced near-maximal suppression of serum dihydrotestosterone (DHT) in phase II dose-ranging work.

Propecia: The 1997 Hair Loss Approval

Propecia (NDA 020788) was approved December 22, 1997, at a dose of 1 mg daily, which reduces serum DHT by roughly 65 to 70% without the volume of distribution required by the BPH dose [2]. The approval covered only men. Women and children were explicitly excluded from the label, and the pregnancy contraindication was retained from the Proscar label because finasteride inhibits the conversion of testosterone to DHT, a step required for normal male fetal genital development.

The key trials submitted with NDA 020788 included two randomized, double-blind, placebo-controlled studies in men aged 18 to 41 with mild to moderate vertex and anterior mid-scalp hair loss. In the vertex baldness study (N=1,215), 48% of men taking finasteride 1 mg showed hair growth vs. 7% in the placebo arm at 2 years [2].

The Kaufman 1998 Confirmatory Trial

Published one year after Propecia's approval, Kaufman et al. (J Am Acad Dermatol 1998, N=1,553) provided additional confirmatory evidence across a broader vertex and anterior scalp evaluation. After 2 years, men on finasteride 1 mg had a net gain of approximately 107 hairs in a 1-inch-diameter target zone, while the placebo group lost approximately 150 hairs in the same zone, a difference of roughly 257 hairs [3]. Global photographic assessment rated 80% of finasteride-treated men as showing no further hair loss or improvement, compared with 47% in the placebo arm.

Generic Entry and Market Expansion

The Hatch-Waxman Act patent clock ran out on the finasteride 5 mg formulation in 2006, opening the generic BPH market. The 1 mg formulation followed, with generic Abbreviated New Drug Applications (ANDAs) approved beginning in 2013. As of 2025, more than a dozen manufacturers hold approved ANDAs for one or both strengths, and finasteride 1 mg is available through telehealth channels at costs well below the branded Propecia price.

Bioequivalence Standards for Generics

Generic finasteride products must demonstrate bioequivalence to the reference listed drug by achieving a 90% confidence interval for the area under the curve (AUC) and peak concentration (Cmax) within the 80 to 125% acceptance window. Finasteride's oral bioavailability is approximately 65%, and its half-life is 5 to 6 hours in younger men (extending to 8 hours in men over 70), so generic sponsors typically use single-dose, fasting crossover pharmacokinetic studies to satisfy FDA bioequivalence requirements [2].

Label Changes After Initial Approval

The finasteride label is a living document. Between 1992 and 2025, CDER has required or accepted multiple revisions based on post-market data, epidemiological studies, and spontaneous adverse-event reports submitted through MedWatch.

2002: Male Breast Cancer Language Added

Following a small cluster of spontaneous reports, the FDA required language noting that male breast cancer had been reported in men taking finasteride. The absolute number of cases remained low, and causality was not established, but the agency applied the precautionary labeling principle. The current Prescribing Information states that physicians should promptly evaluate any breast changes such as lumps, pain, or nipple discharge in patients on finasteride [2].

2011: Prostate Cancer Risk Revision

The largest label revision before 2012 came in 2011, when FDA updated both Proscar and Propecia to reflect findings from the Prostate Cancer Prevention Trial (PCPT). The PCPT (N=18,882 men over 7 years) showed that finasteride 5 mg reduced the overall incidence of prostate cancer by 24.8% relative to placebo. However, a statistically significant increase in high-grade prostate cancer (Gleason score 7 to 10) was detected: 6.4% in the finasteride arm vs. 5.1% in the placebo arm [4].

The FDA's review concluded the data did not support approval of finasteride as a prostate cancer chemoprevention agent, but the label was required to carry the following text (current Proscar Prescribing Information, Section 5.2): "Patients with a large residual urinary volume and/or severely diminished urinary flow should be carefully evaluated for obstructive uropathy and may not be candidates for finasteride therapy." And specifically regarding cancer: "Men taking finasteride 5 mg/day... Had an increased risk of Gleason score 8-10 prostate cancer" [2].

Clinicians should note that the high-grade cancer finding at 5 mg has not been replicated at 1 mg in any adequately powered trial, though the shared mechanism means prescribers and patients are advised to discuss individual prostate cancer risk before starting either dose.

2012: Persistent Sexual Side Effects Warning

In April 2012, FDA required the most discussed label revision in finasteride's history. Both Proscar and Propecia labeling were updated to state that libido disorders, ejaculation disorders, and orgasm disorders may persist after discontinuation of finasteride [5]. The revision acknowledged reports submitted through MedWatch in which men described ongoing sexual dysfunction, depression, and cognitive symptoms months to years after stopping the drug, a cluster of symptoms some researchers call Post-Finasteride Syndrome (PFS).

The 2012 label change did not establish causality. FDA's language was cautious: "In clinical studies for PROPECIA, 1.8% of men taking it reported erectile dysfunction vs. 1.3% of men taking placebo" and "these side effects resolved in men who discontinued therapy" in the majority of clinical trial cases [2]. The persistence language was added based on spontaneous post-market reports rather than controlled trial data.

A practical prescribing framework for discussing this risk with patients is as follows. Before initiating finasteride 1 mg, the clinician should (1) document baseline sexual function using a validated tool such as the International Index of Erectile Function (IIEF-5), (2) discuss the trial-derived adverse event rates (erectile dysfunction 1.8% drug vs. 1.3% placebo; decreased libido 1.8% vs. 1.3%), (3) note the post-market persistence signal without overstating its incidence, and (4) set a 3-month reassessment appointment to evaluate tolerability. This four-step approach brings shared decision-making in line with the FDA's 2012 labeling intent while giving patients a concrete review timeline.

The Pregnancy Category X Designation

Finasteride's Pregnancy Category X (now expressed as a contraindication under the 2014 Pregnancy and Lactation Labeling Rule) is among its most firmly established regulatory features. The drug inhibits the enzyme responsible for converting testosterone to DHT in fetal tissue. Exposure of a male fetus to finasteride during the period of genital differentiation can cause ambiguity in external genitalia [2].

Why Women Cannot Handle Crushed Tablets

The FDA label explicitly states that women who are or may be pregnant must not handle crushed or broken finasteride tablets because the active substance can be absorbed through skin. Intact tablets are coated to prevent contact during normal handling, but the coating is breached when a tablet is cut or crushed. This pharmacokinetic detail has practical implications for any household where a male partner is using finasteride and a pregnant partner might incidentally handle the medication [2].

Lactation Data

No adequate data exist on the presence of finasteride in human breast milk, its effects on the breastfed infant, or its effects on milk production. Because the target population for both approved indications is male, no lactation studies were conducted as part of either NDA. The FDA label advises that the drug is not indicated for use in women [2].

Post-Market Surveillance: FDA Sentinel and MedWatch

Because finasteride is prescribed to large populations of otherwise-healthy men, its post-market pharmacovigilance record is unusually rich. The FDA's Sentinel System, which mines de-identified claims data from more than 100 million lives, has tracked finasteride exposure in the context of depression, self-harm, and sexual dysfunction since the mid-2010s.

Depression and Self-Harm Signal

A 2017 JAMA Internal Medicine analysis (N=93,197 finasteride users) found a statistically significant association between finasteride use and depression, with a hazard ratio of 1.63 (95% CI 1.29 to 2.05, P<0.001) compared with a topical minoxidil reference group [6]. FDA reviewed these data. The agency has not required a black-box warning for depression as of the date of this article's review, but the current label includes a statement that patients should be monitored for depressive symptoms.

Prostate-Specific Antigen (PSA) Interference

Finasteride reduces serum PSA levels by approximately 50% after 6 months of continuous use at the 5 mg dose and by roughly 30 to 40% at the 1 mg dose. This creates a clinically important diagnostic confound: a PSA reading in a man on finasteride should be doubled (for the 5 mg dose) to approximate the actual PSA that would be measured without the drug. The American Urological Association (AUA) guideline on early detection of prostate cancer states that "PSA values in men taking 5-alpha reductase inhibitors should be adjusted before clinical decisions are made" [7].

The Post-Finasteride Syndrome Debate

Post-Finasteride Syndrome is not a recognized FDA-labeled diagnosis. The Post-Finasteride Syndrome Foundation has submitted petitions to FDA requesting a black-box warning, and individual case reports describe persistent sexual dysfunction, depression, cognitive difficulty, and emotional blunting lasting more than 3 months after drug cessation. A 2020 systematic review in the Journal of Sexual Medicine (N=5 observational studies, 4,495 participants) found persistent sexual side effects in 1.4% to 3.4% of men who had used finasteride, though confounding by baseline sexual dysfunction was acknowledged as a limitation [8]. FDA has not changed the label beyond the 2012 persistence language based on this body of evidence to date.

Current Approved Labeling: Key Sections at a Glance

The most recent Proscar (finasteride 5 mg) and Propecia (finasteride 1 mg) prescribing information, accessible through FDA's Drugs@FDA database, contains the following sections relevant to prescribers and patients.

Indications and Usage

Proscar 5 mg: treatment of symptomatic BPH in men with an enlarged prostate (to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of BPH-related surgery). Propecia 1 mg: treatment of male-pattern hair loss (vertex and anterior mid-scalp areas) in men only [2].

Dosage and Administration

One tablet daily, with or without food. No dose adjustment is required for renal impairment. No dose adjustment is required for hepatic impairment in clinical trial data, though the label notes caution because finasteride is metabolized in the liver via CYP3A4 to inactive metabolites [2].

Contraindications

Finasteride is contraindicated in women (specifically those who are or may become pregnant), in pediatric patients, and in individuals with known hypersensitivity to finasteride or any component of the tablet [2].

Warnings and Precautions

The label lists: risk of high-grade prostate cancer (from PCPT data at 5 mg), effects on PSA levels, risk of persistent sexual side effects after discontinuation, and male breast cancer. Allergy and hypersensitivity reactions including rash, pruritus, and angioedema are listed under post-marketing adverse reactions [2].

Comparison of the Two Approved Doses

| Feature | Proscar 5 mg | Propecia 1 mg | |---|---|---| | NDA number | 020145 | 020788 | | Approval date | June 19, 1992 | December 22, 1997 | | Indication | Symptomatic BPH | Male-pattern hair loss | | DHT reduction | ~70% | ~65% | | Generic available | Since 2006 | Since 2013 | | Prostate cancer label | Yes (PCPT data) | No (insufficient data at 1 mg) | | Pregnancy handling warning | Yes | Yes |

Off-Label Use and Regulatory Status

Finasteride is prescribed off-label in several clinical contexts that FDA has not formally reviewed, including gender-affirming care (feminizing hormone therapy as an anti-androgen adjunct), female-pattern hair loss (FPHL), and hirsutism. These uses sit outside the FDA-approved labeling.

Female-Pattern Hair Loss

A Cochrane review published in 2023 identified four randomized controlled trials of finasteride in premenopausal women with FPHL. The pooled evidence was inconclusive due to small sample sizes and heterogeneous outcome measures. The review authors noted that "existing evidence does not support routinely prescribing finasteride to women with female-pattern hair loss outside a clinical trial setting" [9]. FDA has not approved any indication for finasteride in women.

Gender-Affirming Care

Finasteride 2.5 mg to 5 mg daily is used by some clinicians as an alternative or adjunct anti-androgen in transgender women or non-binary individuals assigned male at birth. The Endocrine Society's 2017 clinical practice guideline on gender-dysphoric/gender-incongruent persons lists spironolactone and GnRH agonists as the preferred anti-androgens, with 5-alpha reductase inhibitors as an option. Finasteride's role in this context does not carry FDA approval, and prescribers carry the associated regulatory and liability context [10].

Timeline Summary: Finasteride's Regulatory Milestones

• June 1992: Proscar 5 mg approved by FDA for BPH (NDA 020145)
• December 1997: Propecia 1 mg approved for male androgenetic alopecia (NDA 020788)
• 1998: Kaufman et al. Confirmatory trial published; 107-hair net gain at 2 years vs. Placebo [3]
• 2002: Male breast cancer language added to both labels
• 2006: First generic finasteride 5 mg approved (Hatch-Waxman expiry)
• 2011: Label updated to include high-grade prostate cancer risk from PCPT data
• 2012: Label updated to note possibility of persistent sexual side effects after discontinuation
• 2013: Generic finasteride 1 mg approved
• 2017: FDA reviews depression and self-harm signal from JAMA Internal Medicine analysis
• 2025: No black-box warning added; MedWatch monitoring continues; no new indication approved